Oxsoralen

Vitiligo, Vitiligo, Psoriasis + 3 more
Treatment
20 Active Studies for Oxsoralen

What is Oxsoralen

MethoxsalenThe Generic name of this drug
Treatment SummaryPsoralen is a natural chemical found in some plants, such as Psoralea corylifolia. It becomes activated when exposed to ultraviolet A radiation and binds to DNA molecules.
Oxsoralenis the brand name
Oxsoralen Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Oxsoralen
Methoxsalen
1954
7

Effectiveness

How Oxsoralen Affects PatientsMethoxsalen stops the body from making DNA. The amount of DNA produced is related to how much Methoxsalen is used. If a large amount is used, the production of RNA and proteins in cells will also be reduced.
How Oxsoralen works in the bodyAfter it is activated, this drug binds tightly to the DNA in your cells, creating a link between two strands of DNA. This stops the DNA from carrying out its normal functions, preventing cell growth.

When to interrupt dosage

The advised measure of Oxsoralen is contingent upon the diagnosed disorder, including Palliative Care, Vitiligo and Psoriasis. The dosage amount also fluctuates as per the technique of delivery (e.g. Solution - Extracorporeal or Topical) outlined in the table beneath.
Condition
Dosage
Administration
Vitiligo
, 10.0 mg/mL, 10.0 mg, 0.02 mg/mL, 1.0 %
, Topical, Lotion - Topical, Capsule, liquid filled - Oral, Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Lotion, Capsule, liquid filled, Extracorporeal, Injection, solution, Injection, solution - Extracorporeal, Solution - Extracorporeal, Solution, Capsule - Oral, Capsule, Liquid - Topical, Liquid
Vitiligo
, 10.0 mg/mL, 10.0 mg, 0.02 mg/mL, 1.0 %
, Topical, Lotion - Topical, Capsule, liquid filled - Oral, Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Lotion, Capsule, liquid filled, Extracorporeal, Injection, solution, Injection, solution - Extracorporeal, Solution - Extracorporeal, Solution, Capsule - Oral, Capsule, Liquid - Topical, Liquid
Psoriasis
, 10.0 mg/mL, 10.0 mg, 0.02 mg/mL, 1.0 %
, Topical, Lotion - Topical, Capsule, liquid filled - Oral, Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Lotion, Capsule, liquid filled, Extracorporeal, Injection, solution, Injection, solution - Extracorporeal, Solution - Extracorporeal, Solution, Capsule - Oral, Capsule, Liquid - Topical, Liquid
Lymphoma, T-Cell, Cutaneous
, 10.0 mg/mL, 10.0 mg, 0.02 mg/mL, 1.0 %
, Topical, Lotion - Topical, Capsule, liquid filled - Oral, Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Lotion, Capsule, liquid filled, Extracorporeal, Injection, solution, Injection, solution - Extracorporeal, Solution - Extracorporeal, Solution, Capsule - Oral, Capsule, Liquid - Topical, Liquid
Palliative Treatment
, 10.0 mg/mL, 10.0 mg, 0.02 mg/mL, 1.0 %
, Topical, Lotion - Topical, Capsule, liquid filled - Oral, Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Lotion, Capsule, liquid filled, Extracorporeal, Injection, solution, Injection, solution - Extracorporeal, Solution - Extracorporeal, Solution, Capsule - Oral, Capsule, Liquid - Topical, Liquid
CTAGE1 protein, human
, 10.0 mg/mL, 10.0 mg, 0.02 mg/mL, 1.0 %
, Topical, Lotion - Topical, Capsule, liquid filled - Oral, Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Lotion, Capsule, liquid filled, Extracorporeal, Injection, solution, Injection, solution - Extracorporeal, Solution - Extracorporeal, Solution, Capsule - Oral, Capsule, Liquid - Topical, Liquid

Warnings

Oxsoralen has five contraindications, therefore it should not be taken alongside any of the conditions given in the following table.Oxsoralen Contraindications
Condition
Risk Level
Notes
Aphakia
Do Not Combine
melanoma
Do Not Combine
Squamous cell carcinoma
Do Not Combine
Photophobia
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Oxsoralen.
Common Oxsoralen Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Methoxsalen.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Methoxsalen.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Methoxsalen.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Methoxsalen.
Bendamustine
Major
The metabolism of Bendamustine can be decreased when combined with Methoxsalen.
image of a doctor in a lab doing drug, clinical research

Oxsoralen Novel Uses: Which Conditions Have a Clinical Trial Featuring Oxsoralen?

40 active clinical trials are currently investigating the potential of Oxsoralen to treat Lymphoma, Cutaneous T-Cell Lymphoma, CTAGE1 protein and Human Palliative Care.
Condition
Clinical Trials
Trial Phases
Vitiligo
0 Actively Recruiting
Psoriasis
0 Actively Recruiting
Lymphoma, T-Cell, Cutaneous
0 Actively Recruiting
Vitiligo
7 Actively Recruiting
Phase 2, Phase 3, Phase 1
Palliative Treatment
1 Actively Recruiting
Phase 3
CTAGE1 protein, human
13 Actively Recruiting
Phase 1, Not Applicable, Phase 2, Early Phase 1, Phase 3

Oxsoralen Reviews: What are patients saying about Oxsoralen?

5Patient Review
6/25/2009
Oxsoralen for Severe Psoriasis that is Resistant to Treatment
I find that consuming food an hour before taking the pill helps with any potential nausea. Additionally, I sometimes have trouble sleeping two days after taking the medication; however, this has been my only real complaint.
3.7Patient Review
2/17/2009
Oxsoralen for Severe Psoriasis that is Resistant to Treatment
The medicine has been tough to stomach, even after a couple months of treatment. I've also found myself feeling really exhausted recently, sleeping for up to twelve or fourteen hours straight on weekends.
3Patient Review
5/12/2008
Oxsoralen for Severe Psoriasis that is Resistant to Treatment
3Patient Review
3/15/2010
Oxsoralen for Osteoporosis
This treatment really helped me. I'm grateful for modern medicine.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about oxsoralen

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Ultra drug?

"This medication contains vitamins that are important for the body. They help keep you healthy and can be used to treat or prevent vitamin deficiency."

Answered by AI

What is oxsoralen used for?

"This medication is used in conjunction with exposure to controlled ultraviolet light (UVA) to help alleviate severe psoriasis. It may also be effective for other skin conditions such as vitiligo or cutaneous T-cell lymphoma-CTCL. Methoxsalen works by making the skin more sensitive to UVA light."

Answered by AI

How do you use Melanocyl solution?

"Take this MELANOCYL SOLUTION 25ML by mouth with milk or food, normally 2 to 4 hours before your UVA light treatment. Stay out of the sunlight for 24 hours before taking MELANOCYL SOLUTION 25ML. ... Be extra careful for at least 48 hours after each treatment."

Answered by AI

How do you use methoxsalen?

"For adults and children over the age of 12, apply the product to the affected area of skin and allow it to dry for one to two minutes. Then, reapply within two to two and a half hours before exposure to UV light. For children under the age of 12, dosage and frequency must be determined by a doctor."

Answered by AI

Clinical Trials for Oxsoralen

Image of National Institutes of Health Clinical Center in Bethesda, United States.

CCR4 CAR T Cells for T-Cell Lymphoma

18 - 120
All Sexes
Bethesda, MD
Background: Chemokine receptor 4 (CCR4) is a protein that is found on the surface of certain T-cell lymphoma cells and is common in mature T-cell cancers. White blood cells can be changed with molecules called anti-CCR4 to express a chimeric antigen receptors (CAR), which is a molecule that directs a white blood cell to attack other cells. The CAR in this study attacks the CCR4 protein found on your T-cell lymphoma. This type if therapy is called gene therapy. Gene therapy involves a person s own white blood cells modified to target cancer cells. More research is needed to find out if gene therapy can treat T-cell cancers and do it safely. Objective: To test safety of giving people with certain mature T-cell lymphomas their own white blood cells modified with anti-CCR-4 CAR. Eligibility: People aged 18 and older with certain mature T-cell lymphomas that have not responded to or have come back after treatment. They must have a T-cell lymphoma that has CCR4 on the surface of the cancer cells. Design: Participants will be screened. They will have a medical history and physical exam. Tests of blood, urine, and heart and lung function will be done. Participants will have tests: Computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging scans: They will lie on a table that slides into a donut-shaped machine or a tube. Pictures of the inside of the body will be taken. Before the PET scan, they will get an injection of radioactive fluid in a vein in the arm. Before the MRI, they may get a contrast dye injected through a vein (IV) in the arm. A biopsy of the tumor may be taken. A bone marrow sample may be taken from the hip: The area will be numbed and a large needle inserted through the skin. Leukapheresis will be done to obtain T-cells that will be genetically modified to express anti-CCR4 CARs on T-cells: Blood is drawn through an IV in one arm, circulated through a machine, and then returned through an IV in the other arm. Chemotherapy drugs will be given in an IV to prepare the body to accept the modified CAR T cells. The modified cells will be given in an IV. Participants will be followed for 15 years: This will require blood tests over the first 1-2 years followed by yearly visits and possibly telehealth updates....
Phase 1
Recruiting
National Institutes of Health Clinical CenterSamuel Y Ng, M.D.
Have you considered Oxsoralen clinical trials? We made a collection of clinical trials featuring Oxsoralen, we think they might fit your search criteria.Go to Trials
Image of MedStar Georgetown University Hospital in Washington, United States.

Palliative Care Interventions for Serious Illness

18+
All Sexes
Washington, United States
This stepped-wedge, cluster randomized pragmatic trial among 9 MedStar hospitals for patients with serious illness and unmet palliative care (PC) needs will test two interventions embedded within the electronic health record (EHR): (1) a PC needs triggered alert to opt-in to PC consults nudging hospital clinicians to order specialty PC consults for eligible inpatients, and (2) a palliative care needs triggered alert with an opt-out to palliative care consults. The trial will compare the interventions effects to usual care, focusing on completed PC consults during the hospital encounter and other secondary outcomes. The trial also includes an embedded mixed methods study to explore factors influencing the effectiveness and equity of intervention implementation.
Phase 3
Waitlist Available
MedStar Georgetown University Hospital (+10 Sites)Michael Harhay, PhD, MPH
Image of Marvel Clinical Research in Huntington Beach, United States.

Ritlecitinib for Vitiligo

Any Age
All Sexes
Huntington Beach, CA
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin. Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show: * if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "parent study") will stay the same or will further increase if you keep receiving the same study medicine (ritlecitinib 50 milligrams or placebo) * Or if more repigmentation can be achieved if you start receiving ritlecitinib 100 milligrams in this study * Or how long the repigmentation achieved during the parent study lasts if you start receiving placebo in this study. This study is seeking for participants who: * have non-segmental vitiligo (either active or stable) and * received ritlecitinib or placebo for 52 weeks in the parent study. A placebo looks exactly like the study capsule but does not contain any medicine in it. All participants in this study will receive the study medicine or placebo. The study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. On study visit days, you must take the medication at the study site, and not at home. Participants may receive the study medicine or placebo for up to 52 weeks. The study will look at the experiences of people receiving the study medicine. This will help see if ritlecitinib is better for treating vitiligo. Participants will be involved in this study for a maximum of 60 weeks. During this time, they will have 9 study visits during the study. Ritlecitinib 50 mg is an approved drug for the treatment of severe Alopecia Areata (a disease with similar abnormal changes in the body functions like vitiligo) in the US, EU and Japan. China, Great Britain and other market applications are pending.
Phase 3
Recruiting
Marvel Clinical Research (+34 Sites)Pfizer CT.gov Call CenterPfizer
Have you considered Oxsoralen clinical trials? We made a collection of clinical trials featuring Oxsoralen, we think they might fit your search criteria.Go to Trials
Image of University of Michigan Comprehensive Cancer Center in Ann Arbor, United States.

Pembrolizumab + Mogamulizumab for Cutaneous T-Cell Lymphoma

18+
All Sexes
Ann Arbor, MI
This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles thereafter. Subjects will continue study treatment until documented progression, unacceptable toxicity, or any other condition for discontinuation is met in protocol. A maximum of 2 years of study treatment may be administered. If a subject achieves a complete response (CR) per mSWAT criteria after 3 months of study treatment (2 cycles), they will continue study therapy for an additional 6 months (4 cycles). If a confirmed and persistent CR is met, they may discontinue study treatment and enter an observation period in protocol. Repeat disease evaluation is required prior to study therapy discontinuation. Subjects who progress during the observation period may be eligible for up to an additional 9 cycles (1 year) of pembrolizumab and mogamulizumab.
Phase 2
Recruiting
University of Michigan Comprehensive Cancer CenterRyan WilcoxMerck Sharp & Dohme LLC
Have you considered Oxsoralen clinical trials? We made a collection of clinical trials featuring Oxsoralen, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security